UK markets close in 7 hours 5 minutes

Immunovia AB (publ) (0G8X.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
191.40+154.27 (+415.49%)
As of 05:42PM BST. Market open.
Full screen
Previous close37.13
Bid0.00 x 0
Ask0.00 x 0
Day's range34.49 - 34.49
52-week range34.49 - 34.49
Avg. volumeN/A
Market cap3.697B
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)-7.80
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    SThree: Total Voting Rights

    SThree (STEM) SThree: Total Voting Rights 03-May-2022 / 09:34 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. 3 May 2022 SThree plc Total Voting Rights In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, SThree plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital as at 30 April 2022 consisted of 133,

  • Business Wire

    Immunovia, Inc. Receives Final Approval to Begin Patient Testing with the IMMray® PanCan-d Test

    MARLBOROUGH, Mass., August 04, 2021--Today, Immunovia, Inc., the American subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), announced that it has received final approval to begin patient testing for the IMMray® PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer. This approval was received from the Massachusetts Department of Public Health on August 3, 2021. Immunovia, Inc. received its CLIA Certificate of Registration on June 21, 2021 (C